Should we modify our therapeutic behavior as a consequence of the 2009 revision of the ESH/ESC guidelines for the management of arterial hypertension;¿debemos modificar nuestra conducta terapéutica como consecuencia de la revisión de 2009 de la guía para el manejo de la hipertensión arterial de la ESH/ESC?

Revista Clinica Espanola

Volumn 210, Issue 10, 2010, Pages 511-516

  Calderon A ^a   Escobar, C ^b   Barrios, V ^c  

^a Centro de Salud Rosa Luxemburgo   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

2009 up date; European guidelines; High blood pressure

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL PRACTICE; DIABETIC PATIENT; FEMALE; HUMAN; HYPERTENSION; ORGAN INJURY; PRACTICE GUIDELINE; RISK ASSESSMENT;

AGED; ANTIHYPERTENSIVE AGENTS; DIABETIC ANGIOPATHIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 78049427017     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2010.02.013     Document Type: Article

References (11)

1. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2009 2121 2158
2. American Diabetes Association Standards of Medical Care in Diabetes-2009 Diabetes Care 32 Suppl 1 2009 S13 S61
3. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 2007 1105 1187 (Pubitemid 46924065)
4. L. Hansson, A. Zanchetti, S.G. Caruthers, B. Dahlof, D. Elmfeldt, and S. Julius Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 1998 1755 1762 (Pubitemid 28269185)
5. R.W. Schrier, R.O. Estacio, A. Esler, and P. Mahler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, rethinopathy and stroke Kydney Int 61 2002 1086 1097
6. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial Lancet 370 2007 829 840
7. Antithrombotic Trialists (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
8. H. Ogawa, T. Nakayama, T. Morimoto, S. Uamura, M. Kanauchi, and N. Doi Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomised controlled trial JAMA 300 2008 2134 2141
9. J.F. Mann, R.E. Schmieder, M. McQueen, L. Dyal, H. Schumacher, and J. Pogue Renal outcomes with Telmisartan, Ramipril or both, in people at high cardiovascular risk (the ONTARGET tstudy) a multicentre, randomised, double-blind controlled trial Lancet 372 2008 547 553
10. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto, and J. Kastelein Rosuvastatin to prevent vascular events in man and women with elevated C-reactive protein N Eng J Med 353 2008 2195 2207
11. N.S. Beckett, R. Peters, A.E. Fletcher, J.A. Staessen, L. Liu, and O. Dumitrescu HYVET Study Group Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1882 1898